Comparison of Nebivolol monotherapy versus Nebivolol in combination with other antihypertensive therapies for the treatment of hypertension.

Vasilios Papademetriou

Journal: The American journal of cardiology 2009;103(2):273-8

PMID: 19121451

Full Text on Elsevier Science View on PubMed

Abstract

Nebivolol is a novel, beta1-adrenergic receptor blocker with vasodilatory properties mediated through the activation of the L-arginine/nitric oxide pathway. Short-term randomized clinical trials have demonstrated that nebivolol has antihypertensive efficacy benefits comparable to other beta blockers but with a favorable safety and tolerability profile. The long-term safety and efficacy results of oral nebivolol (5, 10, or 20 mg) 1 time/day, as monotherapy or in combination with other antihypertensive agents, were assessed in a double-blind, multicenter, 9-month extension study of 3 phase III, double-blind, 3-month trials in patients with stage I to II hypertension (mean sitting diastolic blood pressures [BPs]>or=95 and

Address: Hypertension Research, Veterans Administration, and Georgetown University Medical Centers, Washington, DC, USA. [email protected]

DOI: 10.1016/j.amjcard.2008.08.063

Link outs

Free resources

Medical:

https://medlineplus.gov/bloodpressuremedicines.htm...

Subscription / membership required

Full Text Sources:

MeSH Terms: Administration, Oral, Aged, Antihypertensive Agents, Benzopyrans, Double-Blind Method, Drug Therapy, Combination, Ethanolamines, Europe, Female, Humans, Hypertension, Male, Middle Aged, Nebivolol, Placebos, Treatment Outcome, United States